Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
About Cognition Therapeutics Inc.
Cognition Therapeutics Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small-molecule therapeutics targeting age-related degenerative disorders of the central nervous system (CNS) and retina. Founded in 2007 and headquartered in Pittsburgh, Pennsylvania, the company leverages proprietary biology and chemistry platforms to address unmet medical needs in neurodegenerative diseases.
Core Focus and Pipeline
The company’s lead candidate, zervimesine (formerly CT1812), is an orally administered small molecule designed to penetrate the blood-brain barrier and selectively bind to the sigma-2 (σ-2) receptor complex. This novel mechanism aims to displace toxic oligomers of amyloid beta (Aβ) and α-synuclein, which are implicated in the progression of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB). By protecting synapses and restoring cellular function, zervimesine offers a potentially disease-modifying approach distinct from symptomatic treatments.
Cognition Therapeutics is advancing zervimesine through multiple clinical programs:
- Alzheimer’s Disease: The Phase 2 SHINE study demonstrated a 95% reduction in cognitive decline in a biomarker-defined subgroup.
- Dementia with Lewy Bodies (DLB): The SHIMMER Phase 2 trial showed significant improvements across behavioral, cognitive, and motor symptoms, with a favorable safety profile.
- Dry Age-Related Macular Degeneration (dry AMD): The MAGNIFY study explores zervimesine’s potential in slowing lesion growth and addressing retinal degeneration.
Innovative Mechanism of Action
The sigma-2 receptor complex, targeted by zervimesine, regulates key cellular processes such as membrane trafficking and autophagy. These processes are disrupted in neurodegenerative conditions due to toxic protein interactions and oxidative stress. By modulating this receptor, zervimesine aims to normalize synaptic function, protect neurons, and slow disease progression. This mechanism is functionally distinct from other approaches, such as anti-amyloid immunotherapies, positioning Cognition Therapeutics as a pioneer in sigma-2 receptor modulation.
Clinical and Industry Impact
With a strong focus on CNS disorders, Cognition Therapeutics addresses significant unmet needs in Alzheimer’s disease and DLB, which collectively affect millions worldwide. The company’s approach aligns with the growing demand for disease-modifying therapies that go beyond symptomatic relief. Its clinical programs are supported by substantial grant funding from the National Institute on Aging (NIA) and partnerships with leading research institutions.
Challenges and Opportunities
As a clinical-stage company, Cognition Therapeutics faces challenges typical of the biopharmaceutical industry, including high R&D costs, regulatory complexities, and competition from established players. However, its differentiated sigma-2 receptor approach and promising early-phase results provide a strong foundation for future growth. The company’s ability to secure additional funding and advance its pipeline into late-stage trials will be critical to its success.
Conclusion
Cognition Therapeutics Inc. represents a compelling player in the biopharmaceutical sector, leveraging innovative science to address the urgent need for disease-modifying therapies in neurodegenerative disorders. With its lead candidate zervimesine showing promising clinical results, the company is well-positioned to make a meaningful impact on the lives of patients and caregivers affected by Alzheimer’s disease, DLB, and other age-related conditions.
Cognition Therapeutics, Inc. (CGTX) has appointed Paul J. Tiseo, Ph.D., as vice president of clinical development. With over 20 years of experience in CNS drug development, Tiseo will oversee ongoing clinical studies for Alzheimer’s disease and dementia. The company is actively enrolling participants in three studies and plans to start additional studies soon. Tiseo expressed enthusiasm about enhancing development strategies for CT1812, a lead candidate targeting age-related degenerative disorders.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its CEO, Lisa Ricciardi, will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference in San Francisco on October 6-7, 2022. Cognition will be featured in a panel discussion titled ‘Wave of Innovation for Alzheimer’s Disease’ on October 7, 2022, from 9:00 a.m. to 10:00 a.m. PT. The presentation will be exclusive to conference attendees, with no webcast available. Cognition focuses on developing small molecule therapeutics for age-related neurodegenerative diseases, including clinical trials for CT1812 targeting Alzheimer’s and dry AMD.
Cognition Therapeutics has received a $2.14 million grant from the National Institute on Aging to support the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease. This trial aims to assess the impact of CT1812 on EEG patterns linked to memory function. The funding will help advance the study, which has faced delays due to the pandemic. The SEQUEL study involves 16 participants randomized to receive CT1812 or a placebo for 28 days, followed by a crossover period. Previous funding included a $3.2 million grant in 2020.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced management's participation in two September 2022 investment conferences. The H.C. Wainwright 24th Annual Global Investment Conference will occur on September 14, 2022, in New York City, featuring a presentation from 10:30am to 11:00am ET. The Ladenburg Thalmann Healthcare Conference will follow on September 29, 2022, with a presentation from 1:30pm to 1:55pm ET. Live webcasts will be available on the company’s investor website.
Cognition focuses on developing therapeutics for age-related diseases, notably investigating its lead candidate CT1812 for Alzheimer's and related conditions.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) reported optimistic advancements in its clinical trials during Q2 2022, including the initiation of patient dosing in the SHIMMER study for dementia with Lewy bodies and the SHINE study for mild-to-moderate Alzheimer's disease. The company presented promising preclinical data for its dry age-related macular degeneration (dry AMD) program. Financially, CGTX recorded a net loss of $5.8 million for Q2 2022, increasing from $2.8 million in Q2 2021. As of June 30, 2022, the company held $45.8 million in cash and expects to maintain funding into Q4 2023.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) presented insightful findings at the Alzheimer’s Association International Conference on August 4, 2022. Results from the SPARC study highlighted the effects of CT1812 on crucial Alzheimer’s biomarkers, particularly showing a decrease in YKL-40, an inflammation marker, in patients, suggesting a potential therapeutic benefit. Additionally, CT1812 impacted clusterin levels, associated with genetic risks for Alzheimer’s. The company remains optimistic as it proceeds with the ongoing Phase 2 SHINE study.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) will release its second-quarter financial results for the period ending June 30, 2022, on August 9, 2022, before market opening. The company focuses on developing small molecule therapeutics for age-related central nervous system and retinal disorders. Its lead candidate, CT1812, is in clinical trials for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. This announcement highlights the company's ongoing commitment to addressing serious health issues related to aging.
Cognition Therapeutics (NASDAQ: CGTX) announces its participation in the 2022 Alzheimer’s Association International Conference (AAIC) from July 31 to August 4. The company will present new proteomic analyses from the SPARC clinical study, showcasing the impact of CT1812 on Alzheimer’s disease biomarkers. CT1812, an oral small molecule targeting sigma-2 receptors, shows potential therapeutic benefits. Cognition is conducting multiple clinical studies, with results from SHINE and SEQUEL expected in early 2023. The company has secured over $168 million in grant funding.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has initiated its Phase 2 SHIMMER clinical trial for CT1812, targeting dementia with Lewy bodies (DLB). The trial, supported by a $30 million NIA grant, aims to enroll 120 adults aged 50-80 with DLB. CT1812 is an oral therapeutic intended to address DLB's underlying biology, which currently lacks disease-modifying treatments. Primary investigator Dr. James E. Galvin emphasized the trial's importance in exploring a unique mechanism of action against this severe condition.
Cognition Therapeutics (Nasdaq: CGTX) will present at the JMP Securities Life Sciences Conference on June 16, 2022. CEO Lisa Ricciardi will provide an update on the development of small-molecule therapeutics for age-related degenerative diseases. The presentation will focus on their lead candidate, CT1812, which is being studied in clinical programs targeting Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. A live and archived webcast will be available online.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
What is Cognition Therapeutics Inc.'s primary focus?
What is zervimesine (CT1812)?
What is the sigma-2 receptor mechanism?
What clinical trials is Cognition Therapeutics conducting?
How does Cognition Therapeutics differentiate itself from competitors?
What challenges does Cognition Therapeutics face?
What funding supports Cognition Therapeutics’ research?
What is the significance of the SHIMMER trial results?
What are the future plans for zervimesine?
Why is Cognition Therapeutics focusing on neurodegenerative disorders?
